Introduction
Prostate cancer is the second leading cause of cancerrelated death for men in the United States. Advanced stage prostate cancer is usually treated with androgen deprivation therapy (American Cancer Society: Statistics for 2005). Although androgen deprivation therapy may modestly prolong survival, it is palliative and not curative. The vast majority of patients who initially respond to the therapy progress to the highly aggressive, androgen depletion-independent and highly metastatic stage of the disease (Kyprianou et al., 1990; Denis and Murphy, 1993; Epstein et al., 1996; Oh and Kantoff, 1998; Isaacs, 1999) . It is acknowledged that vascular endothelial growth factor-C (VEGF-C) might play a role in the progression and metastatic spread of prostate tumors (Tsurusaki et al., 1999; Jennbacken et al., 2005; Zeng et al., 2005) . VEGF-C has a role in the lymphatic vessel growth and lymph node metastasis (Karpanen et al., 2001; Mandriota et al., 2001; Skobe et al., 2001; He et al., 2002) . Other studies have shown a strong correlation between VEGF-C and its receptor VEGF-R3 (flt4) expression and lymph node metastasis in human prostate carcinoma tissue (Tsurusaki et al., 1999; Jennbacken et al., 2005; Zeng et al., 2005) . Previously, we have shown that in the prostate cancer cell line LNCaP, VEGF-C upregulation can also lead to an increase in androgen receptor co-activator, Bag-1L, suggesting that VEGF-C has the ability to transactivate androgen receptor under low androgen concentrations (Li et al., 2005) . Taken together, these findings suggest multiple functions for VEGF-C in prostate cancer progression. Despite this evidence for the role of VEGF-C in advanced stage prostate cancer, the molecular mechanism involved in VEGF-C expression is still poorly understood. In a previous publication, we show that androgen-ablated conditions and a decrease in insulin-like growth factor 1-receptor (IGF-1R) signaling leads to activation of the forkhead transcription factor FOXO-1 and a concomitant upregulation of VEGF-C mRNA synthesis (Li et al., 2005) . However, the IGF-1R pathway for FOXO-1 activation is not the only pathway involved in the transcriptional regulation of VEGF-C under androgen-ablated conditions. The present study demonstrates the involvement of the small GTPase RalA in the regulation of VEGF-C expression in prostate cancer.
Sequence similarity with H-, K-and N-Ras small G proteins first led to isolation of the Ras-like GTPase, RalA (Chardin and Tavitian, 1986) , now considered a member of the Ras-family of GTPases. Ras family G-proteins are considered to be critical effectors molecules for mediating a variety of cellular responses, including proliferation, differentiation and survival. Specifically, Ral GTPases RalA and RalB have been shown to serve essential functions in vesicle trafficking, cell morphology, transcriptional activation and human oncogenesis (Feig, 2003) . Studies also suggest a role for RalA in tumor metastasis (Tchevkina et al., 2005) and anchorage-independent proliferation (Chien and White, 2003) . In contrast, activation of RalGEF and Ral Ras-effector proteins is not a potent inducer of transformation in rodent fibroblast or epithelial cells (Urano et al., 1996; McFall et al., 2001; Ulku et al., 2003; Collette et al., 2004) . Taken together, these findings suggest that Rasmediated oncogenesis occurs via distinct mechanisms in humans and mice, and highlight RalA and Ral-GEFS as unique potential targets for human cancer therapy.
A role for reactive oxygen species (ROS) in the pathogenesis of prostate cancer has also been well established. Most importantly, ROS may also induce signaling pathways involved in tumor cell survival under stress conditions. For instance, Tam et al. (2003) have shown that androgen deprivation leads to a significant increase in ROS production and the upregulation of ROS-generating nicotinamide adenine dinucleotide phosphate (reduced form) oxidases in rat acinar epithelial cells.
Recently, Essers et al. (2004) have confirmed the small GTPase RalA to be a downstream signaling molecule of ROS. They observed elevated intracellular levels of active or GTP-bound RalA in response to treatment with hydrogen peroxide, causing FOXO-4 nuclear translocation followed by transcriptional activation. These findings linking forkhead transcription factor activation with RalA activity, along with studies establishing a role for ROS and RalA in prostate tumor progression, led us to investigate a possible role for these signaling molecules in VEGF-C transcriptional regulation. Here, we describe a novel mechanism for VEGF-C transcriptional regulation in tumor-derived human prostate carcinoma cell lines.
Results

Androgen deprivation results in increased intracellular ROS generation and VEGF-C synthesis
We have previously shown that in response to androgen deprivation, VEGF-C mRNA and protein levels are elevated (B3-to 7-fold) in a time-dependent manner (Li et al., 2005) . Following our observation that androgen negatively regulates VEGF-C synthesis, publications describing androgen deprivation-induced upregulation of intracellular ROS in the rat prostate came to our attention (Tam et al., 2003) . Based on these published reports, we were curious to analyse whether androgen deprivation could lead to increased ROS generation in the androgen-dependent human prostate carcinoma cell line LNCaP. To do so, we cultured LNCaP cells both in normal and charcoal-dextran (charcoal stripped (CS))-treated (androgen-deprived) serum for 72 h, and then analysed ROS production by flow cytometric detection as described in Materials and methods. Under androgen-depleted conditions, we observed a significant shift in the population positive for increased ROS production, as compared to that for cells cultured in normal serum (Figure 1c ). We were also able to confirm this observation by fluorescence microscopy visualization of intracellular ROS (Figure 1a and b) . These data suggest that androgen deprivation leads to increased ROS generation in the LNCaP prostate carcinoma cell line.
In order to determine whether androgen deprivationinduced ROS generation is a signaling event involved in the regulation of VEGF-C mRNA level, we treated LNCaP cells cultured in CS serum with the generic ROS scavenger N-acetyl-cysteine (NAC). Total RNA was collected and subjected to real-time polymerase chain reaction (PCR) for quantification of VEGF-C mRNA levels. In the presence of the NAC antioxidant, we observed a reduction in VEGF-C mRNA levels, as compared to those for LNCaP cells left untreated with NAC (Po0.05) (Figure 2a ). LNCaP cells treated with NAC were also cultured in CS serum supplemented with synthetic androgen R1881 (10 nM). As shown in Figure 2b , in the presence of synthetic androgen NAC did not show any further inhibition of VEGF-C mRNA level (Po0.05). These data suggest that elevation of intracellular ROS is dependent upon androgen deprivation and is a signaling event involved in the regulation of VEGF-C synthesis.
Figure 1 (a and b) LNCaP prostate carcinoma cells cultured in 10% normal and charcoal-stripped (CS, androgen-deprived) serum were subjected to ROS detection using the Image-iT LIVE Green Reactive Oxygen Species Detection Kit, followed by flow cytometric detection (c) or fluorescence microscopy visualization.
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RalA is activated under androgen-ablated conditions A report by Essers et al. (2004) has implicated the small GTPase RalA as a signaling molecule downstream of increased ROS generation. Recent reports implicating RalA in both human tumorigenic transformation and cancer metastasis led us to question whether RalA could be activated under conditions simulating androgen deprivation therapy, which is commonly used as treatment for advanced stage prostate cancer patients. As such, we chose to assess the involvement of RalA signaling as a downstream event for androgen deprivation-induced ROS generation. To do so, we cultured LNCaP cells under both normal and CS conditions for four different time points, and then performed a pulldown assay for activated RalA-GTP using Ral binding protein 1 (RalBP1) agarose as described in Materials and methods. Protein eluted from the RalBP1 agarose was resolved by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and immunoblotted with antibody against RalA. We found that under androgen-deprived conditions, intracellular levels of active GTP-bound RalA were highly elevated at 72 and 96 h, as compared to RalA-GTP levels for cells under normal serum conditions ( Figure 3a ). Both the 24-and 48-h time points did not show significant upregulation of active RalA ( Figure 3a ). Total RalA levels were comparable between androgen-deprived and non-androgen-deprived cells as determined by Western blot. This finding suggests that RalA is activated within 72 h of androgen deprivation in human prostate carcinoma cells. Of note, our previous findings (Li et al., 2005) also support a significant upregulation of VEGF-C in LNCaP after 72 h under androgen-ablated conditions. We have also observed a detectable increase in ROS level at 72 h after androgen withdrawal ( Figure 1 ). Therefore, taken together, these results suggest that increased synthesis of VEGF-C, ROS and activation of RalA occur at similar time points. In response to the observation that RalA is active under androgen-ablated conditions, we chose to compare active RalA-GTP levels across several prostate carcinoma cell lines. LNCaP and LNCaP syngenic cell lines LNCaP-LN3 and LNCaP-Pro5 were chosen as representative cell lines. The syngenic Pro5 and LN3 cell lines were originally generated by harvesting LNCaP tumor cells from either the prostate or lymph nodes of athymic mice. Pro5 and LN3 characteristically exhibit higher metastatic potential than the parental cell line (LNCaPoPro5oLN3) (Pettaway et al., 1996) . Interestingly, an increase in the metastatic potential of these syngenic cells lines is also associated with a decrease in their growth requirement for androgen (Pettaway et al., 1996) . Both Pro5 and LN3 were generously provided to us by Dr Curtis A Pettaway of MD Anderson. A pulldown immunoblot assay for activated RalA-GTP was Figure 3 (a) LNCaP cells were cultured in 10% normal and CS for 24, 48, 72 and 96 h. Cell lysate was subjected to a pull-down assay for activated RalA-GTP using RalBP1 agarose. Western blot was performed using antibodies for RalA and b-actin internal control. (b) LNCaP, LNCaP-Pro5 and LNCaP-LN3 cell lines were cultured in CS for 72 h. Cell lysates were subjected to pull-down assay for activated RalA-GTP as above; Western blot carried out using antibody for RalA and b-actin internal control.
RalA-ROS signaling axis regulates VEGF-C synthesis F Rinaldo et al performed with the cell lysates from LNCaP, Pro5 and LN3 as described. We observed that as compared to LNCaP, the more metastatic cell lines Pro5 and LN3 exhibited increased RalA activation (Figure 3b ). In contrast, total RalA protein levels were comparable across all cell lines. This observation suggests that increasingly metastatic prostate carcinoma cell lines exhibit higher levels of RalA activation.
RalA activation is ROS signaling-dependent Based on our previous finding that androgen deprivation increases intracellular ROS level, we chose to investigate whether RalA activation is directly regulated by ROS levels in our prostate cancer model. To do so, we cultured LNCaP cells in CS for 72 h, and then treated these cells with generic ROS scavenger NAC (20 mM). Intracellular levels of active (GTP-bound) RalA protein were measured using the pull-down immunoblot method as described previously. As expected, we observed that NAC treatment of LNCaP cells had an inhibitory effect on RalA activation (Figure 4 ).
VEGF-C is a downstream target of RalA signaling
Thus far, our data suggested that androgen ablation of LNCaP prostate carcinoma cells leads to increased intracellular ROS generation and subsequent RalA activation. These findings prompted us to further investigate VEGF-C as a possible downstream target for RalA signaling. Using constitutively active RalA, we first chose to study whether VEGF-C mRNA level is regulated by RalA activation. We infected LNCaP cells cultured in normal serum with a retrovirus carrying the expression vector for the constitutely active Ral Q75L (a generous gift from Dr Chenning Der). Using real-time PCR, we observed an increase in the VEGF-C mRNA level of cells infected with Ral Q75L retrovirus, as compared to those infected with the LacZ control retrovirus (Po0.05) (Figure 5a ). As expected, infection of LNCaP cells with the Ral Q75L retrovirus led to an increase in RalA-GTP levels, as compared to the control (Figure 5b ). Using the RalN28 dominantnegative expression vector kindly provided to us by Dr Johannes L Bos, we then studied whether VEGF-C mRNA level can be downregulated by inhibiting RalA activation. RalN28 is a permanently GDP-bound, dominant-negative form of RalA. LNCaP cells were cultured in CS for 24 h and then transfected for 48 h with the RalN28 dominant-negative expression vector. Total RNA was collected and subjected to real-time PCR for quantification of VEGF-C mRNA levels. Upon transfection of LNCaP cells with the RalN28 dominantnegative, we observed a statistically significant inhibition of VEGF-C mRNA level (Figure 5c ). LNCaP cells transfected with the RalN28 dominant-negative expression vector showed significant expression of the vector as detected by Western blot (Figure 5d) . Additionally, cells transfected with the RalN28 dominant-negative and cultured in CS supplemented with synthetic androgen R1881 did not show any further inhibition of VEGF-C mRNA level (Figure 7b) . We also performed a small interfering RNA knockdown of RalA, which confirmed the inhibitory effect on VEGF-C mRNA level that we had previously observed with the RalN28 dominant-negative (Po0.05) (Figure 5e ) (see Supplement). These findings suggest that inhibition of RalA activity has an inhibitory effect on VEGF-C mRNA level. Taken together, these findings confirm VEGF-C as a downstream target of RalA signaling, and suggest a positive correlation between RalA activation and VEGF-C synthesis.
Androgen ablation induces sequential signaling by ROS and RalA
Based on our previous observation that treatment of LNCaP cells with NAC antioxidant could inhibit VEGF-C mRNA level under androgen-ablated conditions, we sought to confirm the possibility of a sequential ROS-RalA signaling axis. LNCaP cells cultured in CS (androgen ablated) serum were simultaneously infected with a Ral Q75L dominant-active retrovirus and treated with the NAC antioxidant as described in Materials and methods. Although treatment with NAC inhibited VEGF-C mRNA level, infection with the RalA dominant-active retrovirus restored VEGF-C mRNA levels in LNCaP cells treated with NAC (Po0.05) (Figure 6 ). Taken together, these results suggest that increased ROS generation is an upstream signaling event for RalA activation in cells under androgen-ablated conditions. JNK activation is not required for ROS/RalA regulation of VEGF-C transcription From previous reports, c-Jun N-terminal kinase (JNK) appears to be a likely target for ROS-induced RalA signaling (Lo et al., 1996; de Ruiter et al., 2000) . As such, we chose to study whether RalA stimulation of VEGF-C synthesis is mediated by JNK. LNCaP cells were cultured for 24 h in normal and CS, and then transfected for 48 h with either a control vector or the expression vector carrying the dominant-negative form of JNK (JNK1) (kindly provided to us by Dr Roger J Davis of the University of Massachusetts). Total RNA was collected and VEGF-C mRNA levels were quantified by real-time PCR. Upon inhibition of JNK activity by the dominant-negative, we observed a decrease in Figure 4 LNCaP cells were cultured in 10% normal and CS for 72 h. Cells cultured in CS were then treated with 20 mM NAC. Cell lysates were subjected to pull-down assay for active RalA-GTP as described. Western blot was carried out using antibody for RalA.
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F Rinaldo et al VEGF-C mRNA levels for LNCaP cells cultured in androgen-deprived serum, as compared to those for LNCaP cells cultured in CS but transfected with the control vector (Po0.05) (Figure 7a ). LNCaP cells were also transfected with the JNK1 dominant-negative and cultured in CS supplemented with R1881. As expected, addition of androgen to the cell culture did not enhance the inhibitory effect of the JNK dominant-negative on VEGF-C mRNA levels (Figure 7b ). Taken together, these results suggest that JNK is involved in the upregulation of VEGF-C mRNA levels. Next, we chose to determine if JNK is in fact a downstream target of RalA signaling for VEGF-C upregulation upon Figure 5 (a) LNCaP cells cultured in 10% normal serum were infected with low dose (0.4 ml) and high dose (0.8 ml) of RalA Q72L dominant-active retrovirus or LacZ control retrovirus for 48 h. Total RNA was collected and subjected to real-time PCR using primers for VEGF-C and 36B4 internal control. The data presented here represent the mean of three individual experiments. (b) LNCaP cells were cultured in 10% FBS and infected with low (0.4 ml) and high (0.8 ml) dose of the RalA Q72L dominant-active retrovirus and LacZ control retrovirus for 48 h. Whole-cell lysates were collected and subjected to pull-down assay for active RalA-GTP as described. Western blot was carried out using anti-RalA antibody. (c) LNCaP cells cultured in 10% normal and CS conditions were transfected with 1 mg of the RalA N28 dominant-negative expression vector. After transfection for 48 h, total RNA was collected and subjected to real-time PCR using primers specific for VEGF-C and 36B4 internal control. The data presented represent the mean of three individual experiments. (d) LNCaP cells were transiently transfected with RalA N28 for 48 h and cell lysates were collected and resolved using SDS-PAGE. Western blots with anti-FLAG tag and b-actin antibodies were carried out as described previously. (e) LNCaP cells cultured in 10% normal and CS were transfected with 100 nM RalA small interfering RNA for 72 h. Total RNA was collected and subjected to real-time PCR using primers for VEGF-C and 36B4 internal control. The data presented represent the mean of three individual experiments.
Figure 6 LNCaP cells cultured in 10% normal and CS were infected with the Ral Q72L dominant-active retrovirus for 48 h and subsequently treated with NAC antioxidant (20 mM). Total RNA was collected and subjected to real-time PCR using primers for VEGF-C and 36B4 internal control.
RalA-ROS signaling axis regulates VEGF-C synthesis F Rinaldo et al androgen withdrawal. LNCaP cells were again cultured in both normal and CS for 24 h, infected with retroviruses carrying the Ral Q75L dominant-active and LacZ control vectors, and simultaneously transfected with the JNK-1 dominant-negative expression vector for 48 h. Real-time PCR quantification of VEGF-C mRNA levels showed that in cells infected with Ral Q75L retrovirus, transfection with the dominant-negative form of JNK did not inhibit VEGF-C mRNA levels under androgen-ablated conditions (Po0.05) (Figure 7c ). This result suggests that JNK activation may be involved in an additional pathway converging on VEGF-C synthesis, but that it does not seem to be involved for regulation of VEGF-C mRNA levels via RalA signaling.
Discussion
Several cancers show evidence of increased VEGF-C expression during their development and progression (Kimura et al., 2003; Neuchrist et al., 2003; Jia et al., 2004; Sipos et al., 2004) . Elevated VEGF-C protein levels have also been observed in human prostate cancer specimens (Tsurusaki et al., 1999; Jennbacken et al., 2005) . As the molecular pathways contributing to the androgen refractory, highly metastatic stage of prostate cancer are poorly understood, the potential involvement of VEGF-C in the transition to the androgen depletionindependent phenotype of prostate cancer is an important subject area for intense research. Our previous report provided evidence for the increased expression of VEGF-C under androgen-depleted conditions, suggesting a role for this growth factor in promoting the survival of prostate tumor cells during androgen withdrawal (Li et al., 2005) . Based on these findings, it is likely that VEGF-C expression is a critical signal involved in prostate cancer progression to the androgen depletion-independent stage. The present study sought to elucidate one of several molecular pathways leading to the high expression of VEGF-C in prostate cancer under androgen-deprived conditions. An increase in the generation of intracellular ROS owing to androgen withdrawal has been previously reported in rat acinar epithelial cells (Tam et al., 2003) . Here, we show that a similar increase in ROS generation also occurs in prostate cancer cells during androgen withdrawal. As a result of high intracellular levels of ROS, there may be several downstream signaling events contributing to tumorigenesis. One of them, as we observed, is RalA activation leading to VEGF-C production. Activation of RalA has been shown to be important for human cancer progression (Feig, 2003; Tchevkina et al., 2005) . In this light, activation of RalA under androgen-ablated conditions is in itself an important observation, suggesting RalA's possible involvement in the transition of prostate cancer towards the androgen refractory phenotype.
Based on our previous observation that VEGF-C is highly expressed under androgen-ablated conditions (Li et al., 2005) , we questioned whether RalA activation might also regulate VEGF-C expression at low levels of androgen. Our finding that RalA can regulate VEGF-C expression provides an alternative mechanism for regulation of VEGF-C that is distinctly different from that of IGF-IR signaling. To our knowledge, this is the first report suggesting that activation of RalA, an event known for its importance in human oncogenesis, is induced during androgen ablation and leads to VEGF-C Figure 7 (a) LNCaP cells cultured in 10% normal and CS for 72 h were transiently transfected with the JNK-1 dominant-negative expression vector (1 mg) for 48 h. Total RNA was collected and subjected to real-time PCR using primers for VEGF-C and 36B4 internal control. The data presented are the mean of three individual experiments. (b) LNCaP cells were cultured in 10% normal and CS supplemented with 10 nM R1881. The cells were also transiently transfected with the dominant-negative expression vectors for RalA and JNK for 48 h. Total RNA was collected and real-time PCR was performed using primers for VEGF-C and 36B4 internal control. The data presented are the mean of three individual experiments. (c) LNCaP cells were cultured as above, and simultaneously infected with RalA Q72L or LacZ control retroviruses and the JNK-1 dominant-negative expression vector for 48 h. Total RNA was collected and subjected to real-time PCR using primers for VEGF-C and 36B4. The data presented are the mean of three individual experiments.
RalA-ROS signaling axis regulates VEGF-C synthesis F Rinaldo et al synthesis. JNK activation is a known downstream signaling event of ROS (de Ruiter et al., 2000) . Our studies point out that JNK can regulate VEGF-C synthesis. Of note, although RalA can activate JNK in other cell types (Essers et al., 2004) , our study suggests that in prostate cancer cells JNK is not the downstream target of RalA for VEGF-C synthesis. Individually, ROS generation, activation of RalA and increased expression of VEGF-C have been reported by other studies to lead to cancer progression and metastasis by several known mechanisms. In the present study, we not only show that these potent tumor inducers are activated owing to androgen withdrawal in prostate cancer, but also that they are components in a unified, sequential signaling pathway for the production of an important angiogenic growth factor, VEGF-C. Taken together, our findings suggest the existence of a ROS-RalA-VEGF-C signaling axis leading to enhanced VEGF-C synthesis in prostate cancer cells -that may be important for the transition of prostate cancer from androgen dependence to the androgen refractory stage. Hypoxia is one of the strong modulators of VEGF-A synthesis in both physiological and pathological conditions. Interestingly, VEGF-C is not induced by hypoxia. Until now, very little is known about how VEGF-C expression is regulated in cancer cells. Our study is therefore significant because it elucidates a hypoxia-independent molecular pathway involved in induction of VEGF-C production, and thus paves the way for future therapeutic intervention in the treatment of advanced stage prostate cancer.
Materials and methods
Cell culture
Human prostate cancer cell line LNCaP (ATCC # CRL-1740),) and LNCaP syngenic cell lines LNCaP-Pro5 and LNCaP-LN3 were cultured at 371C in Rosewell Park Memorial Institute medium (RPMI) 1640 with L-glutamine (Mediatech Inc., Herndon, VA, USA) supplemented with penicillin/streptomycin and containing either 10% normal fetal bovine serum (FBS) (Hyclone Laboratories, Logan, UT, USA) or 10% charcoal-stripped (CS, androgen-depleted) FBS (Biomeda Corp., Foster City, CA, USA).
ROS detection and ROS scavenger treatment
LNCaP cells were grown in 60 mm cell culture dishes in RPMI containing either 10% normal or CS (androgen-depleted) serum for 72 h. For fluorescence microscopy visualization, cells were grown on glass coverslips placed inside the 60 mm cell culture dishes and then fixed in 4% formaldehyde phosphatebuffered saline. ROS detection was achieved using the ImageiT LIVE Green Reactive Oxygen Species Detection Kit I36007 (Invitrogen Molecular Probes, Carlesbad, CA, USA), followed by either flow cytometric detection or fluorescence microscopy visualization. For treatment with ROS scavenger, LNCaP cells were cultured in RPMI containing 10% normal or CS FBS for 72 h. The cells were then incubated with 20 mM N-acetyl-Lcysteine (NAC) ROS scavenger reagent (Sigma-Aldrich, Saint Louis, MO, USA) at 37.41C for 2 h. Incubation with NAC was followed by total RNA isolation and VEGF-C mRNA quantification by real-time PCR as described below.
Active RalA detection assay LNCaP, LNCaP-Pro5 and LNCaP-LN3 cells were grown in the presence or absence of androgen for 72 and 96 h, lysed with ice-cold radioimmunoprecipitation assay lysis buffer, incubated on ice for 10 min, and centrifuged at 10 000 r.p.m., 41C for 10 min. The pull-down assays were performed using 0.5 mg of cellular protein from whole-cell extracts and 30 ml 50% slurry RalBP1 agarose (Upstate Biotechnology, Lake Placid, NY, USA).
Western blot analysis
The whole-cell extracts were separated by SDS-PAGE; immunodetection antibodies against RalA (Upstate Biotechnology, Lake Placid, NY, USA) and b-actin (Sigma-Aldrich) were used, followed by the secondary antibody incubation and detection by Enhanced Chemiluminescent (ESL) Substrate reagent from Amersham Biosciences Corp (Piscataway, NJ, USA). 
RNA isolation and real-time PCR
Statistics
For comparison between individual groups, t-tests with the assumptions of a two-tail distribution and two samples with equal variance were performed. A P-value below 0.05 was considered significant.
